Randomized multicenter open-label phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa-positive recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second line platinum-based chemotherapy plus bevacizumab(GOG 3078)

Brief description of study

The purposes of this study are: • To determine if mirvetuximab soravtansine (MIRV) plus BEV is effective at managing subjects' type of cancer in a maintenance setting, meaning to assess if it helps to prevent their cancer from returning or delaying their cancer’s return. • To determine if mirvetuximab soravtansine (MIRV) plus BEV is more effective at managing subjects' type of cancer in a maintenance setting than treatment with BEV alone. • To find out what effects, both good and/or bad, MIRV plus BEV may have on subjects and their type of cancer. • To assess if taking MIRV and BEV affects quality of life, both good and/or bad.


Clinical Study Identifier: s22-00972
ClinicalTrials.gov Identifier: NCT05445778
Principal Investigator: Bhavana Pothuri.
Other Investigators: Kelly A Levine, Kent Chan, Michelle Diane Swanson Lightfoot, Emeline Mariam Aviki, Carol M Lee, Edward A Jimenez, Erin Annette Reese, Jonathan B Kahn, Gabrielle Fridman, Fabia Brisard Pierrot, Whitfield B. Growdon, Christina Grace Wilson, Deanna Gerber, Alexander A Hindenburg, Caitlin Elizabeth Ryan, Marina Stasenko, Kathleen M Lutz, Olivia Richardson Khouri, Leslie R Boyd.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.